MAP2K1 and thyroid gland carcinoma: Despite the success of BRAFV600E plus MEK1/2-targeted therapy in melanoma, metastatic NCSLC, and thyroid cancer, the durability of patient response is limited either by primary or acquired chemoresistance [32,33].